Pune, India, September, 2018 /press release/- Market Research Future Published a Half-Cooked Research Report on Protein Microarray Market Research Report.
The global microarray protein market is presumed to expand at 8.2 % CAGR during the forecast period (2017-2023) owing to the advanced diagnosis technology, asserts Market Research Future (MRFR). Also known as protein chips, protein microarray is an emerging class of proteomic technology which has become a major tool in molecular biology and biochemistry. Protein microarray is a miniaturized and parallel array system which comprise purified samples in small amount to distinguish different kinds of protein.
Drivers and Constraints Impacting the Market
Microarray has been considered as the fastest revenue generating and the most efficient technique. With the increasing awareness of personalized medicine among people, development of advanced and efficient diagnosis technology, growing government initiative, and increasing prevalence of cancer are likely to drive the global market during the assessment period. Moreover, improvement in generating high-quality antibodies and proteins is anticipated to play a major role in the quantitative analysis.
On the flip side, proteins are highly sensitive to changes in the microenvironment. Also, the low availability of proteins in the market is likely to hamper the growth of the market in the coming years. Additionally, the declining production of reliable and consistent proteins owing to low yield is presumed to inhibit the market growth over the assessment period.
Global Protein Microarray Market: Segmental Analysis
The global protein microarray market has been segmented on the basis of application, type, technology, product, end-users, and region.
By mode of type, the global protein microarray market has been segmented into lab-on-chips (microfluidics), integrated systems, microarray systems, protein chips, and arrayers.
By mode of application, the market has been segmented into proteomics, diagnostics, antibody characterization, and protein functional analysis.
By mode of product, the market has been segmented into protein microarray services, protein microarray instruments, and protein microarray reagents.
By mode of technology, the market has been segmented into functional protein microarrays, analytical microarrays, and reverse phase protein microarray.
By mode of end-users, the market has been segmented into research centers, diagnostic centers, hospitals, academic institutes, and clinics.
Geographically, the protein microarray market span across regions namely, Europe, America, Asia Pacific, and the Middle East and Africa.
Among all the regions, America is presumed to hold the largest market share during the forecast period owing to the growing prevalence of cancer, rising focus on health care, along with well-established healthcare infrastructure. The United States dominated the global market in this region in terms of revenue in 2017.
The European region is estimated to hold the second largest share in the market and is expected to register a rapid growth owing to the growing research and development activities for developing new drugs along with changing lifestyle.
The Asia Pacific region is presumed to be the fastest growing region owing to the increasing awareness regarding personalized medicine among people, government funding, and growing prevalence of cancer. Moreover, with the adoption of protein chip in countries such as India and China is anticipated to create new opportunities for the market globally.
September 29, 2018: The U.S. Food and Drug Administration is taking the first step towards growing delicious, nutritious, juicy meat in labs, and not farms. The FDA convened their first public hearing to discuss the federal regulation of food grown from cells.
The major players operating the global market are Cepheid Inc. (U.S.), PerkinElmer Inc. (U.S.), Bio-Rad Laboratories Inc. (U.S.), F. Hoffmann-La Roche AG (Genentech) (Switzerland), Illumina Inc. (U.S.), Angioscore Ltd. (U.S.), EMD Millipore (U.S.), GE Healthcare (U.S.), Sigma Aldrich Corporation (U.S.), Abbott Laboratories (U.S.), Agilent Technologies (U.S.), Affymetrix Inc. (U.S.), Fluidigm Corporation (U.S.), Medtronic Inc. (U.S.), Thermo Fisher Scientific (U.S), SEQUENOM Inc. (U.S.), and others.